24
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      International Journal of COPD (submit here)

      This international, peer-reviewed Open Access journal by Dove Medical Press focuses on pathophysiological processes underlying Chronic Obstructive Pulmonary Disease (COPD) interventions, patient focused education, and self-management protocols. Sign up for email alerts here.

      39,063 Monthly downloads/views I 2.893 Impact Factor I 5.2 CiteScore I 1.16 Source Normalized Impact per Paper (SNIP) I 0.804 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Pleural plaques in smoking-associated fibrosis and pulmonary asbestosis

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dear editor Bledsoe et al presents an interesting study examining the disparities between radiologic and pathologic diagnoses of asbestosis in cases referred for consultation in pulmonary malignancy.1 The authors conclude that the clinical diagnosis of asbestosis cannot be reliably distinguished from interstitial fibrosis in heavy smokers. These findings highlight the confounding role of cigarette smoking in the diagnosis of asbestosis when it is based on non-pathologic criteria. Clinical and radiographic characteristics of lung injury following particle exposure (including fibers in which one diameter of the particle is 3× that of the other by definition) are often comparable.2 The results of this investigation1 support further evaluation of a role for cigarette smoking in interstitial fibrosis. Furthermore, asbestos exposure can cause several non-malignant diseases of the pleura and lungs (ie, pleural effusions, pleural plaques, diffuse pleural fibrosis, rounded atelectasis, and asbestosis). Malignancies are also associated with asbestos exposure (ie, lung and laryngeal cancers and mesothelioma).3,4 Relationships between the dose–response and prevalence of asbestos-related diseases are complex.3,5 The injury requiring the least exposure, and which accordingly demonstrates the highest prevalence, is pleural plaque; 80% of individuals significantly exposed to asbestos (total dose of 0.1 fiber-year or less) will have plaques on the chest X-ray while only 0.5%–8% of an unexposed population will reveal such findings.6 Mesothelioma impacts 2,500 to 3,000 workers annually in the United States and its risk is elevated at a total asbestos dose of between 0.1 and 1.0 fiber-year. Those diseases requiring the greatest asbestos exposure are lung cancer and asbestosis; the risk for both is considered elevated at approximately 25 fiber-years. Bledsoe et al identify 24 cases with International Labour Organization (ILO) profusion score of ≥1, out of which only six cases show histological evidence of asbestosis. Of the remaining 18 cases, 16 are identified to have significant smoking history whereas two subjects had unknown smoking status. They observe radiographic evidence of pleural plaques in 82 (44%) of the cases included in the study. It would strengthen the conclusions of the study to know if those diagnosed with asbestosis demonstrated a higher prevalence of pleural plaques than those with cigarette smoking-related fibrosis.1

          Most cited references11

          • Record: found
          • Abstract: not found
          • Article: not found

          Diagnosis and initial management of nonmalignant diseases related to asbestos.

          (2004)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003.

            Using 1973-2000 mesothelioma incidence data released by the Surveillance, Epidemiology, and End Results Program in April 2003, the authors estimated the parameters of a birth-cohort and age model to determine whether previously reported patterns of mesothelioma in the United States have changed. Compared with analyses based on data through 1992, a slower decline was found in male cases immediately after a peak in 2000-2004, but no other notable changes in the time pattern were detected. Analysis confirmed that the annual number of male mesothelioma cases, which increased steeply from the 1970s through the mid-1990s, has leveled off in terms of both the age-adjusted rate and the absolute numbers of cases. After a peak of approximately 2,000 cases, a return to background levels is expected by 2055. The total projected number of male mesothelioma cases in 2003-2054 is approximately 71,000. The maximum lifetime risk for males, which occurs for the 1925-1929 birth cohort, is 1.8 x 10(-3). The age-adjusted rate for females is constant, as are the female lifetime mesothelioma risk across birth cohorts (3.6 x 10(-4)) and the annual risk (3.9 x 10(-6)). The time pattern of cases for females supports the existence of a threshold exposure for mesothelioma and a quantifiable background rate.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Asbestos-related lung disease.

              The inhalation of asbestos fibers may lead to a number of respiratory diseases, including lung cancer, asbestosis, pleural plaques, benign pleural effusion, and malignant mesothelioma. Although exposure is now regulated, patients continue to present with these diseases because of the long latent period between exposure and clinical disease. Presenting signs and symptoms tend to be nonspecific; thus, the occupational history helps guide clinical suspicion. High-risk populations include persons in construction trades, boilermakers, shipyard workers, railroad workers, and U.S. Navy veterans. Every effort should be made to minimize ongoing exposure. Patients with a history of significant asbestos exposure may warrant diagnostic testing and follow-up assessment, although it is unclear whether this improves outcomes. Patients with significant exposure and dyspnea should have chest radiography and spirometry. The prognosis depends on the specific disease entity. Asbestosis generally progresses slowly, whereas malignant mesothelioma has an extremely poor prognosis. The treatment of patients with asbestos exposure and lung cancer is identical to that of any patient with lung cancer. Because exposure to cigarette smoke increases the risk of developing lung cancer in patients with a history of asbestos exposure, smoking cessation is essential. Patients with asbestosis or lung cancer should receive influenza and pneumococcal vaccinations.
                Bookmark

                Author and article information

                Journal
                Int J Chron Obstruct Pulmon Dis
                Int J Chron Obstruct Pulmon Dis
                International Journal of COPD
                International Journal of Chronic Obstructive Pulmonary Disease
                Dove Medical Press
                1176-9106
                1178-2005
                2015
                02 May 2015
                : 10
                : 869-871
                Affiliations
                [1 ]Department of Pulmonary and Critical Care Medicine, West Virginia University, Morgantown, WV, USA
                [2 ]Environmental Public Health Division, National Health and Environmental Effects Research Laboratory, US Environmental Protection Agency, Chapel Hill, NC, USA
                [1 ]Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
                [2 ]Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
                Author notes
                Correspondence: Rahul G Sangani, Department of Pulmonary and Critical Care Medicine, West Virginia University, Robert C Byrd Health Science Center, 1 Medical Center Drive, Morgantown, WV 26505, USA, Tel +1 304 293 4661, Fax +1 304 293 3724, Email rgsangani@ 123456hsc.wvu.edu
                Correspondence: Richard L Kradin, Department of Pathology, Massachusetts General Hospital, Warren Building 253, 55 Fruit Street, Boston, MA 02114, USA, Tel +1 617 726 9029, Fax +1 617 726 7474, Email rkradin@ 123456partners.org
                Article
                copd-10-869
                10.2147/COPD.S83564
                4427072
                25999705
                4e281f1a-f457-4e7a-ba38-33580e4749e8
                © 2015 Sangani et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

                The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

                History
                Categories
                Letter

                Respiratory medicine
                Respiratory medicine

                Comments

                Comment on this article